Patents by Inventor Christopher P. Price

Christopher P. Price has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of C-type natriuretic peptide variants to treat skeletal dysplasia
    Patent number: 11911446
    Abstract: The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: February 27, 2024
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Sherry Bullens, Stuart Bunting, Tianwei Chou, Augustus O. Okhamafe, Christopher P. Price, Daniel J. Wendt, Clarence Yap
  • Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia
    Publication number: 20230293637
    Abstract: The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.
    Type: Application
    Filed: January 20, 2023
    Publication date: September 21, 2023
    Inventors: Sherry Bullens, Stuart Bunting, Tianwei Chou, Augustus O. Okhamafe, Christopher P. Price, Daniel J. Wendt, Clarence Yap
  • Use of C-type natriuretic peptide variants to treat skeletal dysplasia
    Patent number: 11590204
    Abstract: The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: February 28, 2023
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Sherry Bullens, Stuart Bunting, Tianwei Chou, Augustus O. Okhamafe, Christopher P. Price, Daniel J. Wendt, Clarence Yap
  • Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia
    Publication number: 20200246434
    Abstract: The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.
    Type: Application
    Filed: April 1, 2020
    Publication date: August 6, 2020
    Inventors: Sherry Bullens, Stuart Bunting, Tianwei Chou, Augustus O Okhamafe, Christopher P. Price, Daniel J. Wendt, Clarence Yap
  • Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia
    Publication number: 20200246433
    Abstract: The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.
    Type: Application
    Filed: April 1, 2020
    Publication date: August 6, 2020
    Inventors: Sherry Bullens, Stuart Bunting, Tianwei Chou, Augustus O. Okhamafe, Christopher P. Price, Daniel J. Wendt, Clarence Yap
  • Use of C-type natriuretic peptide variants to treat skeletal dysplasia
    Patent number: 10646550
    Abstract: The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: May 12, 2020
    Assignee: BioMarin Pharmaceutical Inc.
    Inventors: Sherry Bullens, Stuart Bunting, Tianwei Chou, Augustus O. Okhamafe, Christopher P. Price, Daniel J. Wendt, Clarence Yap
  • USE OF C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT SKELETAL DYSPLASIA
    Publication number: 20180207239
    Abstract: The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.
    Type: Application
    Filed: January 25, 2018
    Publication date: July 26, 2018
    Applicant: BIOMARIN PHARMACEUTICAL INC.
    Inventors: SHERRY BULLENS, STUART BUNTING, TIANWEI CHOU, AUGUSTUS O. OKHAMAFE, CHRISTOPHER P. PRICE, DANIEL J. WENDT, CLARENCE YAP
  • Use of C-type natriuretic peptide variants to treat skeletal dysplasia
    Patent number: 9907834
    Abstract: The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: March 6, 2018
    Assignee: BioMarin Pharmaceutical Inc.
    Inventors: Sherry Bullens, Stuart Bunting, Tianwei Chou, Augustus O. Okhamafe, Christopher P. Price, Daniel J. Wendt, Clarence Yap
  • Variants of C-Type Natriuretic Peptide
    Publication number: 20170051033
    Abstract: The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).
    Type: Application
    Filed: October 24, 2016
    Publication date: February 23, 2017
    Inventors: Daniel J. Wendt, Shinong Long, Sianna Castillo, Christopher P. Price, Mika Aoyagi-Scharber, Michel Claude Vellard, Augustus O. Okhamafe
  • USE OF C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT SKELETAL DYSPLASIA
    Publication number: 20170028023
    Abstract: The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.
    Type: Application
    Filed: August 1, 2016
    Publication date: February 2, 2017
    Inventors: Sherry Bullens, Stuart Bunting, Tianwei Chou, Augustus O. Okhamafe, Christopher P. Price, Daniel J. Wendt, Clarence Yap
  • Variants of C-Type Natriuretic Peptide
    Publication number: 20160256553
    Abstract: The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).
    Type: Application
    Filed: March 17, 2015
    Publication date: September 8, 2016
    Inventors: Daniel J. Wendt, Shinong Long, Sianna Castillo, Christopher P. Price, Mika Aoyagi-Scharber, Michel Claude Vellard, Augustus O. Okhamafe
  • Variants of C-type natriuretic peptide
    Patent number: 8598121
    Abstract: The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: December 3, 2013
    Assignee: Biomarin Pharmaceutical Inc.
    Inventors: Daniel J. Wendt, Shinong Long, Sianna Castillo, Christopher P. Price, Mika Aoyagi-Scharber, Michel Claude Vellard, Augustus O. Okhamafe
  • Variants of C-type Natriuretic Peptide
    Publication number: 20120316114
    Abstract: The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).
    Type: Application
    Filed: May 8, 2012
    Publication date: December 13, 2012
    Applicant: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Daniel J. Wendt, Shinong Long, Sianna Castillo, Christopher P. Price, Mika Aoyagi-Scharber, Michel C. Vellard, Augustus O. Okhamafe
  • Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
    Patent number: 8252821
    Abstract: Pharmaceutical capsule compositions containing the active compound (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide, and polyethylene glycol (PEG), Vitamin E polyethylene glycol succinate, polyvinylpryrrolidone (PVP) or copovidone (PVP-Polyvinyl acetate), with or without citric acid, are provided.
    Type: Grant
    Filed: April 12, 2010
    Date of Patent: August 28, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Sachin Chandran, Rajesh Babulal Gandhi, Jaquan Kalani Levons, Robert Kevin Perrone, Christopher P. Price, Krishnaswamy Srinivas Raghavan, Ismat Ullah
  • Variants of C-type natriuretic peptide
    Patent number: 8198242
    Abstract: The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: June 12, 2012
    Assignee: Biomarin Pharmaceutical Inc.
    Inventors: Daniel J. Wendt, Shinong Long, Sianna Castillo, Christopher P. Price, Mika Aoyagi-Scharber, Michel C. Vellard, Augustus O. Okhamafe
  • Variants of C-Type Natriuretic Peptide
    Publication number: 20100297021
    Abstract: The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).
    Type: Application
    Filed: May 20, 2010
    Publication date: November 25, 2010
    Applicant: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Daniel J. Wendt, Shinong Long, Sianna Castillo, Christopher P. Price, Mika Aoyagi-Scharber, Michel C. Vellard, Augustus O. Okhamafe
  • Bioavailable Capsule Compositions of Amorphous Alpha-(N-Sulfonamido)Acetamide Compound
    Publication number: 20100260837
    Abstract: Pharmaceutical capsule compositions containing the active compound (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide, and polyethylene glycol (PEG), Vitamin E polyethylene glycol succinate, polyvinylpryrrolidone (PVP) or copovidone (PVP-Polyvinyl acetate), with or without citric acid, are provided.
    Type: Application
    Filed: April 12, 2010
    Publication date: October 14, 2010
    Inventors: Sachin Chandran, Rajesh Babulal Gandhi, Jaquan Kalani Levons, Robert Kevin Perrone, Christopher P. Price, Krishnaswamy Srinivas Raghavan, Ismat Ullah
  • Assay of salicylates or reduced pyridine nucleotides
    Patent number: 5460948
    Abstract: A method for the estimation of a salicylate in a sample is characterized by enzymatically converting the salicylate to a catechol by the action of a salicylate mono-oxygenase enzyme on the salicylate in the presence of a reduced pyridine nucleotide, reacting the catechol with a compound selected from compounds of formula I or amine or phenolic compounds of formulae II, III or IV ##STR1##
    Type: Grant
    Filed: August 19, 1993
    Date of Patent: October 24, 1995
    Assignee: The Public Health Laboratory Service Board
    Inventors: Anthony Atkinson, Stewart R. Cambell, Peter M. Hammond, Helen C. Morris, John R. Ramsey, Christopher P. Price
  • Variants of C-type natriuretic peptide
    Patent number: RE46707
    Abstract: The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: February 13, 2018
    Assignee: BioMarin Pharmaceutical Inc.
    Inventors: Daniel J. Wendt, Shinong Long, Sianna Castillo, Christopher P. Price, Mika Aoyagi-Scharber, Michel Claude Vellard, Augustus O. Okhamafe
  • Variants of C-type natriuretic peptide
    Patent number: RE48267
    Abstract: The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: October 20, 2020
    Assignee: BioMarin Pharmaceutical Inc.
    Inventors: Daniel J. Wendt, Shinong Long, Sianna Castillo, Christopher P. Price, Mika Aoyagi-Scharber, Michel Claude Vellard, Augustus O. Okhamafe